Harry P. Erba, MD, PhD Harry P. Erba, MD, PhD

Harry P. Erba, MD, PhD

Cell Therapy and Hematologic Malignancies Specialist

No ratings available.
question Circle Img
Duke Health Provider What's this?
Insurance

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy

Click to see a list of accepted insurance plansHide accepted insurance plans
Contact
919-684-8964 Office number
919-684-8964
Fax number
Insurance

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy

Click to see a list of accepted insurance plansHide accepted insurance plans

Contact
WHERE I PROVIDE CARE
Profile
ABOUT ME

I entered medical school for the sole purpose of learning more about human diseases, so that I could focus my laboratory efforts on improving the human condition. However, I was surprised to find myself drawn to clinical care. I care for people afflicted by acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. In this role, I have had the privilege of treating people facing life-threatening illnesses. I strive to gain the trust of each of my patients, so that I can help them make difficult treatment decisions. I engage in clinical research, evaluating novel agents that directly target the cancer cell to improve the degree of success in treating this illness. My patients benefit from my understanding of the newest available treatments, and also have access to promising investigational agents, when appropriate. In my faculty position at Duke University, I enjoy educating current oncologists as well as the next generation of physicians.

LANGUAGES I SPEAK
English
Training
EDUCATION
MD, Stanford University School of Medicine (California), 1988
RESIDENCY
Internal Medicine, Brigham and Women's Hospital (Massachusetts), 1988-1990
FELLOWSHIP
Hematology-Oncology, Harvard Medical School, Brigham & Women's Hospital (Massachusetts), 1990-1993
BOARD CERTIFICATION
American Board of Internal Medicine, Hematology
Clinical Focus and Research
MY RESEARCH INTERESTS

I treat people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). In general, therapies initially developed for these cancers were drugs that killed cells that are dividing. Unfortunately, many normal cells in the body are also affected or killed by these drugs as well, leading to the unwanted toxicities of chemotherapy. Over the years, we have gained tremendous insight into the specific events that cause a cell to become cancerous and have developed better tools for distinguishing normal from cancerous cells. My clinical research effort for over 20 years has focused on the development of drugs that specifically target the abnormalities of the leukemia cell. I study the effects associated with treating people with investigational agents that target the molecular changes that are specific to blood cancers. I have been an active member of teams of doctors that have brought new treatments to people with leukemia, such as oral drugs that inactivate FLT3 and IDH. In this way we hope to improve the outcome of people with blood cancers with fewer unwanted side effects.

PUBLICATIONS
View Harry Erba's publications on PubMed
Industry Relationships and Collaborations
This faculty member has no reported relationships with industry.